Galen
As of the edition of 20 October 2026, Galen runs 3 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Daunorubicin | none listed | 2 |
| Estradiol | Ends 2032 (patent) | 6 |
| Estradiol acetate | none listed | 1 |
A route B row is one company at one target.